Show simple item record

 
dc.contributorDepartament de Salut
dc.contributor.authorPrograma d'Harmonització Farmacoterapèutica
dc.date.accessioned2019-06-12T10:13:52Z
dc.date.available2019-06-12T10:13:52Z
dc.date.issued2019-02-01
dc.identifier.citationPrograma d'Harmonització Farmacoterapèutica. Ibrutinib per al tractament de la leucèmia limfocítica crònica. Barcelona: Servei Català de la Salut; 2019.
dc.identifier.urihttp://hdl.handle.net/11351/4131
dc.descriptionIbrutinib; Monotherapy; Chronic lymphocytic leukemia
dc.description.abstractChronic lymphocytic leukemia (LLC) is the most frequent type of leukemia in adults in the western world, representing 25-50% of all leukemia. The median age at diagnosis is 72 years and only 10% of patients are <55 years. It has a prevalence of 3.5 cases / 10,000 inhabitants and an annual incidence of 5 new cases / 100,000 inhabitants. The incidence increases to> 30 cases / 100,000 / year in patients> 70 years. It affects more frequently men than women (2: 1)
dc.language.isocat
dc.publisherServei Català de la Salut
dc.relation.ispartofPrograma d'Harmonització Farmacoterapèutica, Servei Català de la Salut
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectLeucèmia limfocítica crònica - Tractament
dc.subjectMedicaments - Assaigs clínics
dc.subject.meshLeukemia, Lymphocytic, Chronic, B-Cell
dc.subject.mesh/drug therapy
dc.subject.meshDrug Evaluation
dc.titleIbrutinib per al tractament de la leucèmia limfocítica crònica
dc.typeinfo:eu-repo/semantics/report
dc.subject.decsleucemia linfocítica crónica de células B
dc.subject.decs/tratamiento farmacológico
dc.subject.decsevaluación de medicamentos
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record